( April 7, 2025, 16:12 GMT | Official Statement) -- MLex Summary: Sandoz, Glenmark, and other pharmaceutical companies said that US states have failed to sufficiently allege an overarching conspiracy among pharmaceutical companies in a case over generic drug pricing, moving for a summary judgment. “Even the states’ cooperating witnesses — the witnesses who, if any overarching conspiracy existed, could be expected to say so in clear, definitive, and unequivocal terms — rejected the notion that any overarching conspiracy existed. Those witnesses also testified that there were independent reasons to engage in the conduct that the States attribute to conspiracy,” they said. See attached file. ...
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.